496 research outputs found

    Changes in kidney function in a population with essential hypertension in real life settings

    Get PDF
    Introduction. Hypertension has been identified as one of the commonest modifiable determinants for chronic kidney disease progression. A variety of antihypertensive drugs are available and their effect on kidney function has been investigated by a large number of randomized controlled trials. Observational studies, although scarcely been used, outpatient can reflect everyday practice, where drug exposures vary over time, and may provide an alternative for detecting longitudinal changes in kidney function. Materials and Methods. We applied mixed model repeated measures analysis to investigate the effect of antihypertensive drug categories and their combinations on kidney function change over time in a cohort of 779 patients with essential hypertension, using the data from a Greek hypertension outpatient clinic. Antihypertensive drugs were grouped in 5 categories. Their effect was evaluated and their combinations with and without renin-angiotensin-system inhibitors (RASI) to each other. In addition, the combination of RASI with calcium channel blockers (CCBs) was studied. Results. Diuretics, RASI, CCBs, and beta-blockers had a significant renoprotective and blood pressure lowering effect. Combinations with RASI had a smaller beneficial effect on kidney function compared to CCBs (0.75 mL/min/1.73 m2 per year of drug use versus 0.97 mL/min/1.73 m2). There was no additional effect when combining RASI with CCBs. However, the lowering effect on systolic blood pressure was greater (-0.83 mm Hg per year of drug use, P < .001). Conclusions. RASI were found to have a smaller, although significant, renoprotective effect. There was no additional effect on kidney function when combining RASI with CCBs

    Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis.

    Get PDF
    OBJECTIVE: To evaluate the efficacy and safety of artificial pancreas treatment in non-pregnant outpatients with type 1 diabetes. DESIGN: Systematic review and meta-analysis of randomised controlled trials. DATA SOURCES: Medline, Embase, Cochrane Library, and grey literature up to 2 February 2018. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials in non-pregnant outpatients with type 1 diabetes that compared the use of any artificial pancreas system with any type of insulin based treatment. Primary outcome was proportion (%) of time that sensor glucose level was within the near normoglycaemic range (3.9-10 mmol/L). Secondary outcomes included proportion (%) of time that sensor glucose level was above 10 mmol/L or below 3.9 mmol/L, low blood glucose index overnight, mean sensor glucose level, total daily insulin needs, and glycated haemoglobin. The Cochrane Collaboration risk of bias tool was used to assess study quality. RESULTS: 40 studies (1027 participants with data for 44 comparisons) were included in the meta-analysis. 35 comparisons assessed a single hormone artificial pancreas system, whereas nine comparisons assessed a dual hormone system. Only nine studies were at low risk of bias. Proportion of time in the near normoglycaemic range (3.9-10.0 mmol/L) was significantly higher with artificial pancreas use, both overnight (weighted mean difference 15.15%, 95% confidence interval 12.21% to 18.09%) and over a 24 hour period (9.62%, 7.54% to 11.7%). Artificial pancreas systems had a favourable effect on the proportion of time with sensor glucose level above 10 mmol/L (-8.52%, -11.14% to -5.9%) or below 3.9 mmol/L (-1.49%, -1.86% to -1.11%) over 24 hours, compared with control treatment. Robustness of findings for the primary outcome was verified in sensitivity analyses, by including only trials at low risk of bias (11.64%, 9.1% to 14.18%) or trials under unsupervised, normal living conditions (10.42%, 8.63% to 12.2%). Results were consistent in a subgroup analysis both for single hormone and dual hormone artificial pancreas systems. CONCLUSIONS: Artificial pancreas systems are an efficacious and safe approach for treating outpatients with type 1 diabetes. The main limitations of current research evidence on artificial pancreas systems are related to inconsistency in outcome reporting, small sample size, and short follow-up duration of individual trials

    Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension

    Get PDF
    10openopenKonstas A.G.; Quaranta L.; Katsanos A.; Riva I.; Tsai J.C.; Giannopoulos T.; Voudouragkaki I.C.; Paschalinou E.; Floriani I.; Haidich A.B.Konstas, A. G.; Quaranta, Luciano; Katsanos, A.; Riva, Ivano; Tsai, J. C.; Giannopoulos, T.; Voudouragkaki, I. C.; Paschalinou, E.; Floriani, I.; Haidich, A. B

    The importance of colonization pressure in multiresistant Acinetobacter baumannii acquisition in a Greek intensive care unit

    Get PDF
    INTRODUCTION: We investigated the role of colonization pressure on multiresistant Acinetobacter baumannii acquisition and defined patient-related predictors for carriage at admission and acquisition during hospitalization in intensive care unit (ICU) patients. METHODS: This was a 12-month, prospective, cohort study of all patients admitted to a single ICU of a tertiary hospital. Screening samples were collected at ICU admission to identify imported carriers, and weekly during hospitalization to identify acquisition. Colonization pressure (carriers' patient-days × 100/all patients' patient-days) and the absolute number of carriers were calculated weekly, and the statistical correlation between these parameters and acquisition was explored. Multivariable analysis was performed to identify predictors for A. baumannii carriage at admission and acquisition during hospitalization. A. baumannii isolates were genotyped by repetitive-extragenic-palindromic polymerase chain reaction (PCR; rep-PCR). RESULTS: At ICU admission, 284 patients were screened for carriage. A. baumannii was imported in 16 patients (5.6%), and acquisition occurred in 32 patients (15.7%). Acquisition was significantly correlated to weekly colonization pressure (correlation coefficient, 0.379; P = 0.004) and to the number of carriers per week (correlation coefficient, 0.499; P <0.001). More than one carrier per week significantly increased acquisition risk (two to three carriers, odds ratio (OR), 12.66; P = 0.028; more than four carriers, OR, 25.33; P = 0.004). Predictors of carriage at admission were infection at admission (OR, 11.03; confidence interval (CI), 3.56 to 34.18; P < 0.01) and hospitalization days before ICU (OR, 1.09; CI, 1.01 to 1.16; P = 0.02). Predictors of acquisition were a medical reason for ICU admission (OR, 5.11; CI, 1.31 to 19.93; P = 0.02), duration of antibiotic administration in the unit (OR, 1.24; CI, 1.12 to 1.38; P < 0.001), and duration of mechanical ventilation (OR, 1.08; CI, 1.04 to 1.13; P = 0.001). All strains were multiresistant. Rep-PCR analysis showed one dominant cluster. CONCLUSIONS: Acquisition of multiresistant A. baumannii in ICU patients is strongly correlated to colonization pressure. High levels of colonization pressure and more than two carriers per week independently increase acquisition risk. Patient-related factors, such as infection at admission and long hospitalization before the ICU, can identify imported A. baumannii carriers. Medical patients with extended administration of antibiotics and long duration of mechanical ventilation in the ICU were the most vulnerable to acquisition

    Low-carbohydrate vs low-fat diets for the secondary prevention of cardiovascular diseases. A meta-analysis

    Get PDF
    The scientific evidence surrounding the efficacy of low-carbohydrate diets (LCDs) compared to low-fat diets (LFDs) in the secondary prevention of cardiometabolic diseases is diverse. While some studies indicate that LCDs can lead to superior cardiometabolic outcomes(1), others conclude that higher intakes of MUFA, or PUFA could have a better impact on the risk of CVD(2). However, despite inconclusive findings, only a limited number of reviews have employed precise meta-analytical methods and used the most recent scientific evidence to derive quantitative estimates of the relative effect of these two diets.// This study aims to exploit the advantages of meta-analysis to compare the efficacy of LCDs (CHO <30% of total energy intake) and LFDs (FAT <35% of total energy intake) against cardiovascular diseases (CVDs), based on the most recent scientific evidence.// A systematic review was performed by retrieving studies from 5 bibliographic databases from January 2013 to 31 May 2023. The studied population included adults at high risk for CVDs, and the outcomes covered indicators for glycemic control, adiposity, lipidemia, and inflammation. Data were extracted in a pre-defined template and a meta-analysis was performed, along with sensitivity analyses. This abstract provides a preliminary analysis of outcomes from a subset of identified studies, focusing on two specific parameters, including triacylglycerols (TGs) and Body Mass Index (BMI).// Six studies (769 subjects) were included in the meta-analysis. Overall, participants in the LCD had on average 0.30 mmol/L lower TG levels at the end of the intervention (95% CI: −0.43; −0.17) whilst for participants in the LFD the magnitude of the effect was smaller (i.e., −0.22 (−0.36; −0.08) mmol/L). However, we found no evidence of a significant impact of the LCD on TG levels against the LFD (change in mean difference (95% CI): −0.096 (−0.245; 0.053) mmol/L), whilst study heterogeneity was moderate (I2 = 56%). Moreover, participants in the LCD achieved a reduction in BMI of -2.04 kg/m2 on average (95% CI: -2.77; -1.31), whilst those in LFD achieved on average a reduction of -1.20 kg/m2 in BMI (95% CI: -1.95; −0.44), with the reduction in BMI being greater for participants in the LCD compared to the LFD (−0.47 kg/m2 (−0.91; −0.04), I2 = 12%).// The findings of this pairwise meta-analysis underscore the complex interplay between dietary composition and metabolic outcomes and will provide the best practices for the risk reduction of developing CVDs

    The impact of oral food challenges for food allergy on quality of life:a systematic review

    Get PDF
    BACKGROUND: Food allergy significantly impairs health-related quality of life (HRQL). Currently, it is still unknown whether diagnostic interventions for food allergy improve HRQL. We aim to assess the impact of diagnostic interventions for food allergy on HRQL. METHODS: A systematic search was performed in MEDLINE, Embase, Cochrane Library and CINAHL focused on patients with a (suspected) food allergy who underwent diagnostic interventions (i.e. skin prick test, specific IgE or oral food challenges (OFC)), and in whom HRQL was assessed. The mean difference between HRQL before and after the diagnostic intervention was calculated. A minimal clinically important difference of 0.5 was considered clinically relevant for the Food Allergy Quality of Life Questionnaire . RESULTS: Seven of 1465 original identified publications were included in which the impact of an OFC on HRQL was investigated (total patients n=1370). No other diagnostic interventions were investigated. Food allergy specific parent-reported HRQL improved significantly after an OFC irrespective of the outcome in children with a suspected food allergy in two publications. The change was considered clinically relevant in one of two publications. In addition, parent-reported HRQL improved after an OFC to assess the eliciting dose in children with a confirmed food allergy. The parental burden was significantly reduced after an OFC to assess resolution of food allergy. A meta-analysis could not be performed due to the limited numbers of, and considerable heterogeneity between, eligible publications. CONCLUSION: An OFC is associated with an improved food allergy specific HRQL and a reduced parental burden of food allergy. This article is protected by copyright. All rights reserved

    Initial assessment and follow-up of a myopic child: A clinical evaluation tool

    Get PDF
    Myopia comprises the leading cause of visual impairment in childhood, showing a global rapid rise in prevalence over the past years.  Myopia progression has been related with a number of ocular complications potentially resulting in blindness, including glaucoma, macular degeneration, cataract, and retinal detachment. Etiopathogenesis of this disorder is regarded multifactorial, involving both environmental and genetic components. Near work activities are believed to play a key role in myopic development, owing to the induced hyperopic defocus on the peripheral retina that may result in axial elongation. Other parameters including outdoor exposure, physical activity and digital screen time are also hypothesized to be connected with myopic development. Ocular examination of myopic subjects should include visual acuity assessment, refraction, biometry and choroidal thickness measurements, as well as evaluation of the accommodative functions. We propose a clinical assessment tool, as a useful guide for all eye care professionals examining and treating juvenile myopes

    Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions : A Systematic Review

    Get PDF
    BACKGROUND: We performed a systematic review to assess whether we can quantify the underreporting of adverse events (AEs) in the published medical literature documenting the results of clinical trials as compared with other nonpublished sources, and whether we can measure the impact this underreporting has on systematic reviews of adverse events. METHODS AND FINDINGS: Studies were identified from 15 databases (including MEDLINE and Embase) and by handsearching, reference checking, internet searches, and contacting experts. The last database searches were conducted in July 2016. There were 28 methodological evaluations that met the inclusion criteria. Of these, 9 studies compared the proportion of trials reporting adverse events by publication status. The median percentage of published documents with adverse events information was 46% compared to 95% in the corresponding unpublished documents. There was a similar pattern with unmatched studies, for which 43% of published studies contained adverse events information compared to 83% of unpublished studies. A total of 11 studies compared the numbers of adverse events in matched published and unpublished documents. The percentage of adverse events that would have been missed had each analysis relied only on the published versions varied between 43% and 100%, with a median of 64%. Within these 11 studies, 24 comparisons of named adverse events such as death, suicide, or respiratory adverse events were undertaken. In 18 of the 24 comparisons, the number of named adverse events was higher in unpublished than published documents. Additionally, 2 other studies demonstrated that there are substantially more types of adverse events reported in matched unpublished than published documents. There were 20 meta-analyses that reported the odds ratios (ORs) and/or risk ratios (RRs) for adverse events with and without unpublished data. Inclusion of unpublished data increased the precision of the pooled estimates (narrower 95% confidence intervals) in 15 of the 20 pooled analyses, but did not markedly change the direction or statistical significance of the risk in most cases. The main limitations of this review are that the included case examples represent only a small number amongst thousands of meta-analyses of harms and that the included studies may suffer from publication bias, whereby substantial differences between published and unpublished data are more likely to be published. CONCLUSIONS: There is strong evidence that much of the information on adverse events remains unpublished and that the number and range of adverse events is higher in unpublished than in published versions of the same study. The inclusion of unpublished data can also reduce the imprecision of pooled effect estimates during meta-analysis of adverse events
    corecore